ID   P3C2A_HUMAN             Reviewed;        1686 AA.
AC   O00443; B0LPH2; B4E2G4; Q14CQ9;
DT   30-AUG-2005, integrated into UniProtKB/Swiss-Prot.
DT   10-JUL-2007, sequence version 2.
DT   28-JUN-2023, entry version 202.
DE   RecName: Full=Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha;
DE            Short=PI3K-C2-alpha;
DE            Short=PtdIns-3-kinase C2 subunit alpha;
DE            EC=2.7.1.137 {ECO:0000269|PubMed:10766823, ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:9337861};
DE            EC=2.7.1.153 {ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:9337861};
DE            EC=2.7.1.154 {ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:9337861};
DE   AltName: Full=Phosphoinositide 3-kinase-C2-alpha;
GN   Name=PIK3C2A;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM 1), FUNCTION, CATALYTIC ACTIVITY,
RP   COFACTOR, ACTIVITY REGULATION, BIOPHYSICOCHEMICAL PROPERTIES, AND TISSUE
RP   SPECIFICITY.
RX   PubMed=9337861; DOI=10.1042/bj3260139;
RA   Domin J., Pages F., Volinia S., Rittenhouse S.E., Zvelebil M.J.,
RA   Stein R.C., Waterfield M.D.;
RT   "Cloning of a human phosphoinositide 3-kinase with a C2 domain which
RT   displays reduced sensitivity to the inhibitor wortmannin.";
RL   Biochem. J. 326:139-147(1997).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Trachea;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RG   NHLBI resequencing and genotyping service (RS&G);
RL   Submitted (DEC-2007) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16554811; DOI=10.1038/nature04632;
RA   Taylor T.D., Noguchi H., Totoki Y., Toyoda A., Kuroki Y., Dewar K.,
RA   Lloyd C., Itoh T., Takeda T., Kim D.-W., She X., Barlow K.F., Bloom T.,
RA   Bruford E., Chang J.L., Cuomo C.A., Eichler E., FitzGerald M.G.,
RA   Jaffe D.B., LaButti K., Nicol R., Park H.-S., Seaman C., Sougnez C.,
RA   Yang X., Zimmer A.R., Zody M.C., Birren B.W., Nusbaum C., Fujiyama A.,
RA   Hattori M., Rogers J., Lander E.S., Sakaki Y.;
RT   "Human chromosome 11 DNA sequence and analysis including novel gene
RT   identification.";
RL   Nature 440:497-500(2006).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L., Mobarry C.M.,
RA   Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R., Flanigan M.J.,
RA   Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V., Hannenhalli S.,
RA   Turner R., Yooseph S., Lu F., Nusskern D.R., Shue B.C., Zheng X.H.,
RA   Zhong F., Delcher A.L., Huson D.H., Kravitz S.A., Mouchard L., Reinert K.,
RA   Remington K.A., Clark A.G., Waterman M.S., Eichler E.E., Adams M.D.,
RA   Hunkapiller M.W., Myers E.W., Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 1).
RC   TISSUE=Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND SUBCELLULAR
RP   LOCATION.
RX   PubMed=10766823; DOI=10.1074/jbc.275.16.11943;
RA   Domin J., Gaidarov I., Smith M.E.K., Keen J.H., Waterfield M.D.;
RT   "The class II phosphoinositide 3-kinase PI3K-C2alpha is concentrated in the
RT   trans-Golgi network and present in clathrin-coated vesicles.";
RL   J. Biol. Chem. 275:11943-11950(2000).
RN   [8]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, AND IDENTIFICATION IN A COMPLEX
RP   WITH ERBB2 AND EGFR.
RX   PubMed=10805725; DOI=10.1128/mcb.20.11.3817-3830.2000;
RA   Arcaro A., Zvelebil M.J., Wallasch C., Ullrich A., Waterfield M.D.,
RA   Domin J.;
RT   "Class II phosphoinositide 3-kinases are downstream targets of activated
RT   polypeptide growth factor receptors.";
RL   Mol. Cell. Biol. 20:3817-3830(2000).
RN   [9]
RP   SUBCELLULAR LOCATION, NUCLEAR LOCALIZATION SIGNAL, PHOSPHORYLATION, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=11606566; DOI=10.1074/jbc.m104610200;
RA   Didichenko S.A., Thelen M.;
RT   "Phosphatidylinositol 3-kinase c2alpha contains a nuclear localization
RT   sequence and associates with nuclear speckles.";
RL   J. Biol. Chem. 276:48135-48142(2001).
RN   [10]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, SUBCELLULAR LOCATION,
RP   INTERACTION WITH CLATHRIN, AND MUTAGENESIS OF 103-LEU--ASP-107.
RX   PubMed=11239472; DOI=10.1016/s1097-2765(01)00191-5;
RA   Gaidarov I., Smith M.E.K., Domin J., Keen J.H.;
RT   "The class II phosphoinositide 3-kinase C2alpha is activated by clathrin
RT   and regulates clathrin-mediated membrane trafficking.";
RL   Mol. Cell 7:443-449(2001).
RN   [11]
RP   SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX   PubMed=14563213; DOI=10.1186/1472-6890-3-4;
RA   El Sheikh S.S., Domin J., Tomtitchong P., Abel P., Stamp G., Lalani E.-N.;
RT   "Topographical expression of class IA and class II phosphoinositide 3-
RT   kinase enzymes in normal human tissues is consistent with a role in
RT   differentiation.";
RL   BMC Clin. Pathol. 3:4-4(2003).
RN   [12]
RP   FUNCTION, PHOSPHORYLATION AT SER-259, MUTAGENESIS OF SER-254; SER-259;
RP   SER-262 AND SER-266, LACK OF PHOSPHORYLATION AT SER-244; SER-249; SER-251;
RP   SER-254; SER-262 AND SER-266, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=12719431; DOI=10.1074/jbc.m301657200;
RA   Didichenko S.A., Fragoso C.M., Thelen M.;
RT   "Mitotic and stress-induced phosphorylation of HsPI3K-C2alpha targets the
RT   protein for degradation.";
RL   J. Biol. Chem. 278:26055-26064(2003).
RN   [13]
RP   FUNCTION IN ASSEMBLY AND CELLULAR DISTRIBUTION OF CLATHRIN, INTERACTION
RP   WITH CLATHRIN, MUTAGENESIS OF ASP-1250, AND REGION.
RX   PubMed=16215232; DOI=10.1074/jbc.m507731200;
RA   Gaidarov I., Zhao Y., Keen J.H.;
RT   "Individual phosphoinositide 3-kinase C2alpha domain activities
RT   independently regulate clathrin function.";
RL   J. Biol. Chem. 280:40766-40772(2005).
RN   [14]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108 AND SER-259, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-60; SER-108; SER-259 AND
RP   SER-338, AND IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18669648; DOI=10.1073/pnas.0805139105;
RA   Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,
RA   Elledge S.J., Gygi S.P.;
RT   "A quantitative atlas of mitotic phosphorylation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008).
RN   [16]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RX   PubMed=19413330; DOI=10.1021/ac9004309;
RA   Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J., Mohammed S.;
RT   "Lys-N and trypsin cover complementary parts of the phosphoproteome in a
RT   refined SCX-based approach.";
RL   Anal. Chem. 81:4493-4501(2009).
RN   [17]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-259, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [18]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-259, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Leukemic T-cell;
RX   PubMed=19690332; DOI=10.1126/scisignal.2000007;
RA   Mayya V., Lundgren D.H., Hwang S.-I., Rezaul K., Wu L., Eng J.K.,
RA   Rodionov V., Han D.K.;
RT   "Quantitative phosphoproteomic analysis of T cell receptor signaling
RT   reveals system-wide modulation of protein-protein interactions.";
RL   Sci. Signal. 2:RA46-RA46(2009).
RN   [19]
RP   FUNCTION IN DYNAMIN-INDEPENDENT ENDOCYTOSIS.
RX   PubMed=21081650; DOI=10.1242/jcs.071712;
RA   Krag C., Malmberg E.K., Salcini A.E.;
RT   "PI3KC2alpha, a class II PI3K, is required for dynamin-independent
RT   internalization pathways.";
RL   J. Cell Sci. 123:4240-4250(2010).
RN   [20]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108 AND SER-259, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [21]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P., Buerckstuemmer T.,
RA   Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [22]
RP   TISSUE SPECIFICITY.
RX   PubMed=21127054; DOI=10.1074/jbc.m110.200295;
RA   Dominguez V., Raimondi C., Somanath S., Bugliani M., Loder M.K.,
RA   Edling C.E., Divecha N., da Silva-Xavier G., Marselli L., Persaud S.J.,
RA   Turner M.D., Rutter G.A., Marchetti P., Falasca M., Maffucci T.;
RT   "Class II phosphoinositide 3-kinase regulates exocytosis of insulin
RT   granules in pancreatic beta cells.";
RL   J. Biol. Chem. 286:4216-4225(2011).
RN   [23]
RP   REVIEW ON FUNCTION.
RX   PubMed=17371240; DOI=10.1042/bst0350211;
RA   Falasca M., Maffucci T.;
RT   "Role of class II phosphoinositide 3-kinase in cell signalling.";
RL   Biochem. Soc. Trans. 35:211-214(2007).
RN   [24]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-259 AND SER-327, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21406692; DOI=10.1126/scisignal.2001570;
RA   Rigbolt K.T., Prokhorova T.A., Akimov V., Henningsen J., Johansen P.T.,
RA   Kratchmarova I., Kassem M., Mann M., Olsen J.V., Blagoev B.;
RT   "System-wide temporal characterization of the proteome and phosphoproteome
RT   of human embryonic stem cell differentiation.";
RL   Sci. Signal. 4:RS3-RS3(2011).
RN   [25]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-108; SER-259; SER-327;
RP   SER-630; SER-1281 AND SER-1553, AND IDENTIFICATION BY MASS SPECTROMETRY
RP   [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma, and Erythroleukemia;
RX   PubMed=23186163; DOI=10.1021/pr300630k;
RA   Zhou H., Di Palma S., Preisinger C., Peng M., Polat A.N., Heck A.J.,
RA   Mohammed S.;
RT   "Toward a comprehensive characterization of a human cancer cell
RT   phosphoproteome.";
RL   J. Proteome Res. 12:260-271(2013).
RN   [26]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-259, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=24275569; DOI=10.1016/j.jprot.2013.11.014;
RA   Bian Y., Song C., Cheng K., Dong M., Wang F., Huang J., Sun D., Wang L.,
RA   Ye M., Zou H.;
RT   "An enzyme assisted RP-RPLC approach for in-depth analysis of human liver
RT   phosphoproteome.";
RL   J. Proteomics 96:253-262(2014).
RN   [27]
RP   FUNCTION, INVOLVEMENT IN OCSKD, VARIANT OCSKD 195-TYR--LEU-1686 DEL, AND
RP   CHARACTERIZATION OF VARIANT OCSKD 195-TYR--LEU-1686 DEL.
RX   PubMed=31034465; DOI=10.1371/journal.pgen.1008088;
RA   Tiosano D., Baris H.N., Chen A., Hitzert M.M., Schueler M., Gulluni F.,
RA   Wiesener A., Bergua A., Mory A., Copeland B., Gleeson J.G., Rump P.,
RA   van Meer H., Sival D.A., Haucke V., Kriwinsky J., Knaup K.X., Reis A.,
RA   Hauer N.N., Hirsch E., Roepman R., Pfundt R., Thiel C.T., Wiesener M.S.,
RA   Aslanyan M.G., Buchner D.A.;
RT   "Mutations in PIK3C2A cause syndromic short stature, skeletal
RT   abnormalities, and cataracts associated with ciliary dysfunction.";
RL   PLoS Genet. 15:E1008088-E1008088(2019).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 1405-1544, PHOSPHOINOSITIDE
RP   BINDING, SUBCELLULAR LOCATION, AND MUTAGENESIS OF ARG-1488; VAL-1490;
RP   LEU-1491; ARG-1493 AND ARG-1503.
RX   PubMed=17038310; DOI=10.1074/jbc.m607079200;
RA   Stahelin R.V., Karathanassis D., Bruzik K.S., Waterfield M.D., Bravo J.,
RA   Williams R.L., Cho W.;
RT   "Structural and membrane binding analysis of the Phox homology domain of
RT   phosphoinositide 3-kinase-C2alpha.";
RL   J. Biol. Chem. 281:39396-39406(2006).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.80 ANGSTROMS) OF 1421-1532.
RA   Parkinson G.N., Vines D., Driscoll P.C., Djordjevic S.;
RT   "Ligand-binding specificity of PI3kinase C2alpha PX domain.";
RL   Submitted (OCT-2006) to the PDB data bank.
CC   -!- FUNCTION: Generates phosphatidylinositol 3-phosphate (PtdIns3P) and
CC       phosphatidylinositol 3,4-bisphosphate (PtdIns(3,4)P2) that act as
CC       second messengers. Has a role in several intracellular trafficking
CC       events. Functions in insulin signaling and secretion. Required for
CC       translocation of the glucose transporter SLC2A4/GLUT4 to the plasma
CC       membrane and glucose uptake in response to insulin-mediated RHOQ
CC       activation. Regulates insulin secretion through two different
CC       mechanisms: involved in glucose-induced insulin secretion downstream of
CC       insulin receptor in a pathway that involves AKT1 activation and
CC       TBC1D4/AS160 phosphorylation, and participates in the late step of
CC       insulin granule exocytosis probably in insulin granule fusion.
CC       Synthesizes PtdIns3P in response to insulin signaling. Functions in
CC       clathrin-coated endocytic vesicle formation and distribution. Regulates
CC       dynamin-independent endocytosis, probably by recruiting EEA1 to
CC       internalizing vesicles. In neurosecretory cells synthesizes PtdIns3P on
CC       large dense core vesicles. Participates in calcium induced contraction
CC       of vascular smooth muscle by regulating myosin light chain (MLC)
CC       phosphorylation through a mechanism involving Rho kinase-dependent
CC       phosphorylation of the MLCP-regulatory subunit MYPT1. May play a role
CC       in the EGF signaling cascade. May be involved in mitosis and UV-induced
CC       damage response. Required for maintenance of normal renal structure and
CC       function by supporting normal podocyte function. Involved in the
CC       regulation of ciliogenesis and trafficking of ciliary components
CC       (PubMed:31034465). {ECO:0000269|PubMed:10766823,
CC       ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11239472,
CC       ECO:0000269|PubMed:12719431, ECO:0000269|PubMed:16215232,
CC       ECO:0000269|PubMed:21081650, ECO:0000269|PubMed:31034465,
CC       ECO:0000269|PubMed:9337861}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol 4-
CC         phosphate) + ATP = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-3,4-bisphosphate) + ADP + H(+); Xref=Rhea:RHEA:18373,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:57658,
CC         ChEBI:CHEBI:58178, ChEBI:CHEBI:456216; EC=2.7.1.154;
CC         Evidence={ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11239472,
CC         ECO:0000269|PubMed:9337861};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:18374;
CC         Evidence={ECO:0000305|PubMed:9337861};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol) + ATP = a
CC         1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-3-phosphate) + ADP +
CC         H(+); Xref=Rhea:RHEA:12709, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:57880, ChEBI:CHEBI:58088, ChEBI:CHEBI:456216;
CC         EC=2.7.1.137; Evidence={ECO:0000269|PubMed:10766823,
CC         ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:11239472,
CC         ECO:0000269|PubMed:9337861};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:12710;
CC         Evidence={ECO:0000305|PubMed:9337861};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-inositol-4,5-
CC         bisphosphate) + ATP = a 1,2-diacyl-sn-glycero-3-phospho-(1D-myo-
CC         inositol-3,4,5-trisphosphate) + ADP + H(+); Xref=Rhea:RHEA:21292,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:57836,
CC         ChEBI:CHEBI:58456, ChEBI:CHEBI:456216; EC=2.7.1.153;
CC         Evidence={ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:9337861};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:21293;
CC         Evidence={ECO:0000305|PubMed:9337861};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108;
CC         Evidence={ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:9337861};
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:9337861};
CC       Note=Ca(2+) or Mg(2+). Mn(2+) cannot be used.
CC       {ECO:0000269|PubMed:10805725, ECO:0000269|PubMed:9337861};
CC   -!- ACTIVITY REGULATION: Activated by insulin (By similarity). Only
CC       slightly inhibited by wortmannin and LY294002. Activated by clathrin.
CC       {ECO:0000250|UniProtKB:Q61194, ECO:0000269|PubMed:10766823,
CC       ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:9337861}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=122 uM for PtdIns (in the absence of phosphatidylserine)
CC         {ECO:0000269|PubMed:9337861};
CC         KM=64 uM for PtdIns (in the presence of phosphatidylserine)
CC         {ECO:0000269|PubMed:9337861};
CC         KM=25 uM for PtdIns4P (in the presence of phosphatidylserine)
CC         {ECO:0000269|PubMed:9337861};
CC         KM=15 uM for ATP (with PtdIns as substrate) (in the absence of
CC         phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         KM=32 uM for ATP (with PtdIns as substrate) (in the presence of
CC         phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         KM=54 uM for ATP (with PtdIns4P as substrate) (in the presence of
CC         phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         Vmax=990 pmol/min/mg enzyme with PtdIns as substrate (in the absence
CC         of phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         Vmax=200 pmol/min/mg enzyme with PtdIns as substrate (in the presence
CC         of phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         Vmax=240 pmol/min/mg enzyme with PtdIns4P as substrate (in the
CC         presence of phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         Vmax=6800 pmol/min/mg enzyme toward ATP with PtdIns as substrate (in
CC         the absence of phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         Vmax=805 pmol/min/mg enzyme toward ATP with PtdIns as substrate (in
CC         the presence of phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         Vmax=880 pmol/min/mg enzyme toward ATP with PtdIns4P as substrate (in
CC         the presence of phosphatidylserine) {ECO:0000269|PubMed:9337861};
CC         Note=In the absence of the carrier phosphatidylserine, enzymatic
CC         kinetics toward PtdIns4P are non-linear.;
CC   -!- SUBUNIT: Part of a complex with ERBB2 and EGFR (PubMed:10805725).
CC       Interacts with clathrin trimers (PubMed:11239472, PubMed:16215232).
CC       Interacts with SBF2/MTMR13 (By similarity).
CC       {ECO:0000250|UniProtKB:Q61194, ECO:0000269|PubMed:10805725,
CC       ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:16215232}.
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:10766823,
CC       ECO:0000269|PubMed:11239472, ECO:0000269|PubMed:17038310}. Cytoplasmic
CC       vesicle, clathrin-coated vesicle {ECO:0000269|PubMed:10766823,
CC       ECO:0000269|PubMed:11239472}. Nucleus {ECO:0000269|PubMed:11606566}.
CC       Cytoplasm {ECO:0000269|PubMed:11606566, ECO:0000269|PubMed:14563213}.
CC       Golgi apparatus, trans-Golgi network {ECO:0000269|PubMed:10766823,
CC       ECO:0000269|PubMed:11239472}. Note=Inserts preferentially into
CC       membranes containing PtdIns(4,5)P2 (PubMed:17038310). Associated with
CC       RNA-containing structures (PubMed:11606566).
CC       {ECO:0000269|PubMed:11606566, ECO:0000269|PubMed:17038310}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=O00443-1; Sequence=Displayed;
CC       Name=2;
CC         IsoId=O00443-2; Sequence=VSP_056158;
CC   -!- TISSUE SPECIFICITY: Expressed in columnar and transitional epithelia,
CC       mononuclear cells, smooth muscle cells, and endothelial cells lining
CC       capillaries and small venules (at protein level). Ubiquitously
CC       expressed, with highest levels in heart, placenta and ovary, and lowest
CC       levels in the kidney. Detected at low levels in islets of Langerhans
CC       from type 2 diabetes mellitus individuals.
CC       {ECO:0000269|PubMed:14563213, ECO:0000269|PubMed:21127054,
CC       ECO:0000269|PubMed:9337861}.
CC   -!- PTM: Phosphorylated upon insulin stimulation; which may lead to enzyme
CC       activation (By similarity). Phosphorylated on Ser-259 during mitosis
CC       and upon UV irradiation; which does not change enzymatic activity but
CC       leads to proteasomal degradation. Ser-259 phosphorylation may be
CC       mediated by CDK1 or JNK, depending on the physiological state of the
CC       cell. {ECO:0000250|UniProtKB:Q61194, ECO:0000269|PubMed:11606566,
CC       ECO:0000269|PubMed:12719431}.
CC   -!- DISEASE: Oculoskeletodental syndrome (OCSKD) [MIM:618440]: An autosomal
CC       recessive syndrome characterized by congenital cataracts, short
CC       stature, dysmorphic features with coarse facies, dental anomalies,
CC       multiple skeletal abnormalities, and neurological manifestations. Other
CC       recurrent features include hearing loss, secondary glaucoma, and
CC       nephrocalcinosis. {ECO:0000269|PubMed:31034465}. Note=The disease is
CC       caused by variants affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the PI3/PI4-kinase family. {ECO:0000255|PROSITE-
CC       ProRule:PRU00879, ECO:0000255|PROSITE-ProRule:PRU00880}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Y13367; CAA73797.1; -; mRNA.
DR   EMBL; AK304262; BAG65126.1; -; mRNA.
DR   EMBL; EU332862; ABY87551.1; -; Genomic_DNA.
DR   EMBL; AC107956; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC116533; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC126389; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471064; EAW68447.1; -; Genomic_DNA.
DR   EMBL; BC113658; AAI13659.1; -; mRNA.
DR   CCDS; CCDS7824.1; -. [O00443-1]
DR   PIR; PC4345; PC4345.
DR   RefSeq; NP_001308307.1; NM_001321378.1. [O00443-1]
DR   RefSeq; NP_002636.2; NM_002645.3. [O00443-1]
DR   RefSeq; XP_016873413.1; XM_017017924.1.
DR   PDB; 2AR5; X-ray; 1.80 A; A=1421-1532.
DR   PDB; 2IWL; X-ray; 2.60 A; X=1405-1544.
DR   PDB; 2REA; X-ray; 2.50 A; A=1421-1532.
DR   PDB; 2RED; X-ray; 2.10 A; A=1421-1532.
DR   PDB; 6BTY; X-ray; 1.68 A; A/B=1559-1686.
DR   PDB; 6BTZ; X-ray; 1.85 A; A/B/C/D=1559-1686.
DR   PDB; 6BU0; X-ray; 2.43 A; A/B/C=1559-1686.
DR   PDB; 6BUB; X-ray; 2.60 A; A=1405-1544.
DR   PDBsum; 2AR5; -.
DR   PDBsum; 2IWL; -.
DR   PDBsum; 2REA; -.
DR   PDBsum; 2RED; -.
DR   PDBsum; 6BTY; -.
DR   PDBsum; 6BTZ; -.
DR   PDBsum; 6BU0; -.
DR   PDBsum; 6BUB; -.
DR   AlphaFoldDB; O00443; -.
DR   SASBDB; O00443; -.
DR   SMR; O00443; -.
DR   BioGRID; 111304; 184.
DR   CORUM; O00443; -.
DR   DIP; DIP-33727N; -.
DR   ELM; O00443; -.
DR   IntAct; O00443; 64.
DR   MINT; O00443; -.
DR   STRING; 9606.ENSP00000265970; -.
DR   BindingDB; O00443; -.
DR   ChEMBL; CHEMBL1075102; -.
DR   GuidetoPHARMACOLOGY; 2150; -.
DR   SwissLipids; SLP:000000892; -.
DR   GlyCosmos; O00443; 3 sites, 1 glycan.
DR   GlyGen; O00443; 7 sites, 1 O-linked glycan (7 sites).
DR   iPTMnet; O00443; -.
DR   PhosphoSitePlus; O00443; -.
DR   SwissPalm; O00443; -.
DR   BioMuta; PIK3C2A; -.
DR   EPD; O00443; -.
DR   jPOST; O00443; -.
DR   MassIVE; O00443; -.
DR   MaxQB; O00443; -.
DR   PaxDb; O00443; -.
DR   PeptideAtlas; O00443; -.
DR   ProteomicsDB; 47892; -. [O00443-1]
DR   ProteomicsDB; 5816; -.
DR   Antibodypedia; 24799; 759 antibodies from 34 providers.
DR   DNASU; 5286; -.
DR   Ensembl; ENST00000265970.11; ENSP00000265970.6; ENSG00000011405.14. [O00443-1]
DR   Ensembl; ENST00000691414.1; ENSP00000509400.1; ENSG00000011405.14. [O00443-1]
DR   GeneID; 5286; -.
DR   KEGG; hsa:5286; -.
DR   MANE-Select; ENST00000691414.1; ENSP00000509400.1; NM_002645.4; NP_002636.2.
DR   UCSC; uc001mmq.6; human. [O00443-1]
DR   AGR; HGNC:8971; -.
DR   CTD; 5286; -.
DR   DisGeNET; 5286; -.
DR   GeneCards; PIK3C2A; -.
DR   HGNC; HGNC:8971; PIK3C2A.
DR   HPA; ENSG00000011405; Low tissue specificity.
DR   MalaCards; PIK3C2A; -.
DR   MIM; 603601; gene.
DR   MIM; 618440; phenotype.
DR   neXtProt; NX_O00443; -.
DR   OpenTargets; ENSG00000011405; -.
DR   Orphanet; 557003; Oculoskeletodental syndrome.
DR   PharmGKB; PA33304; -.
DR   VEuPathDB; HostDB:ENSG00000011405; -.
DR   eggNOG; KOG0905; Eukaryota.
DR   GeneTree; ENSGT00940000157813; -.
DR   HOGENOM; CLU_002191_0_2_1; -.
DR   InParanoid; O00443; -.
DR   OMA; HQWPALY; -.
DR   OrthoDB; 10350at2759; -.
DR   PhylomeDB; O00443; -.
DR   TreeFam; TF102031; -.
DR   BioCyc; MetaCyc:HS00315-MON; -.
DR   BRENDA; 2.7.1.154; 2681.
DR   PathwayCommons; O00443; -.
DR   Reactome; R-HSA-1660499; Synthesis of PIPs at the plasma membrane.
DR   Reactome; R-HSA-1660514; Synthesis of PIPs at the Golgi membrane.
DR   Reactome; R-HSA-1660516; Synthesis of PIPs at the early endosome membrane.
DR   Reactome; R-HSA-1660517; Synthesis of PIPs at the late endosome membrane.
DR   Reactome; R-HSA-432722; Golgi Associated Vesicle Biogenesis.
DR   Reactome; R-HSA-8856828; Clathrin-mediated endocytosis.
DR   SABIO-RK; O00443; -.
DR   SignaLink; O00443; -.
DR   SIGNOR; O00443; -.
DR   BioGRID-ORCS; 5286; 19 hits in 1172 CRISPR screens.
DR   ChiTaRS; PIK3C2A; human.
DR   EvolutionaryTrace; O00443; -.
DR   GeneWiki; PIK3C2A; -.
DR   GenomeRNAi; 5286; -.
DR   Pharos; O00443; Tchem.
DR   PRO; PR:O00443; -.
DR   Proteomes; UP000005640; Chromosome 11.
DR   RNAct; O00443; protein.
DR   Bgee; ENSG00000011405; Expressed in secondary oocyte and 214 other tissues.
DR   ExpressionAtlas; O00443; baseline and differential.
DR   Genevisible; O00443; HS.
DR   GO; GO:0030136; C:clathrin-coated vesicle; IDA:UniProtKB.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; IDA:HPA.
DR   GO; GO:0070062; C:extracellular exosome; HDA:UniProtKB.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:HPA.
DR   GO; GO:0016020; C:membrane; HDA:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:HPA.
DR   GO; GO:0005942; C:phosphatidylinositol 3-kinase complex; IBA:GO_Central.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005802; C:trans-Golgi network; IDA:UniProtKB.
DR   GO; GO:0031982; C:vesicle; IDA:UniProtKB.
DR   GO; GO:0016303; F:1-phosphatidylinositol-3-kinase activity; IDA:UniProtKB.
DR   GO; GO:0035005; F:1-phosphatidylinositol-4-phosphate 3-kinase activity; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0030276; F:clathrin binding; IDA:UniProtKB.
DR   GO; GO:0035004; F:phosphatidylinositol 3-kinase activity; TAS:UniProtKB.
DR   GO; GO:0035091; F:phosphatidylinositol binding; IEA:InterPro.
DR   GO; GO:0052812; F:phosphatidylinositol-3,4-bisphosphate 5-kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0046934; F:phosphatidylinositol-4,5-bisphosphate 3-kinase activity; IDA:UniProtKB.
DR   GO; GO:0016477; P:cell migration; IBA:GO_Central.
DR   GO; GO:0048268; P:clathrin coat assembly; TAS:UniProtKB.
DR   GO; GO:0006897; P:endocytosis; IMP:UniProtKB.
DR   GO; GO:0007173; P:epidermal growth factor receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0006887; P:exocytosis; TAS:UniProtKB.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0061024; P:membrane organization; TAS:Reactome.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IBA:GO_Central.
DR   GO; GO:0006661; P:phosphatidylinositol biosynthetic process; TAS:ProtInc.
DR   GO; GO:0036092; P:phosphatidylinositol-3-phosphate biosynthetic process; IBA:GO_Central.
DR   GO; GO:0048008; P:platelet-derived growth factor receptor signaling pathway; TAS:UniProtKB.
DR   GO; GO:0010508; P:positive regulation of autophagy; IMP:CACAO.
DR   GO; GO:0090050; P:positive regulation of cell migration involved in sprouting angiogenesis; IMP:BHF-UCL.
DR   GO; GO:0014829; P:vascular associated smooth muscle contraction; TAS:UniProtKB.
DR   CDD; cd04012; C2A_PI3K_class_II; 1.
DR   CDD; cd08381; C2B_PI3K_class_II; 1.
DR   CDD; cd00869; PI3Ka_II; 1.
DR   CDD; cd05176; PI3Kc_C2_alpha; 1.
DR   CDD; cd07289; PX_PI3K_C2_alpha; 1.
DR   Gene3D; 2.60.40.150; C2 domain; 2.
DR   Gene3D; 1.10.1070.11; Phosphatidylinositol 3-/4-kinase, catalytic domain; 1.
DR   Gene3D; 1.25.40.70; Phosphatidylinositol 3-kinase, accessory domain (PIK); 1.
DR   Gene3D; 3.30.1520.10; Phox-like domain; 1.
DR   InterPro; IPR016024; ARM-type_fold.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000403; PI3/4_kinase_cat_dom.
DR   InterPro; IPR036940; PI3/4_kinase_cat_sf.
DR   InterPro; IPR018936; PI3/4_kinase_CS.
DR   InterPro; IPR037705; PI3K-C2-alpha_dom.
DR   InterPro; IPR002420; PI3K-type_C2_dom.
DR   InterPro; IPR001263; PI3K_accessory_dom.
DR   InterPro; IPR042236; PI3K_accessory_sf.
DR   InterPro; IPR000341; PI3K_Ras-bd_dom.
DR   InterPro; IPR015433; PI_Kinase.
DR   InterPro; IPR001683; PX_dom.
DR   InterPro; IPR036871; PX_dom_sf.
DR   InterPro; IPR042133; PX_PI3K_C2_alpha.
DR   InterPro; IPR029071; Ubiquitin-like_domsf.
DR   PANTHER; PTHR10048:SF28; PHOSPHATIDYLINOSITOL 4-PHOSPHATE 3-KINASE C2 DOMAIN-CONTAINING SUBUNIT ALPHA; 1.
DR   PANTHER; PTHR10048; PHOSPHATIDYLINOSITOL KINASE; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF00454; PI3_PI4_kinase; 1.
DR   Pfam; PF00792; PI3K_C2; 1.
DR   Pfam; PF00794; PI3K_rbd; 1.
DR   Pfam; PF00613; PI3Ka; 1.
DR   Pfam; PF00787; PX; 1.
DR   SMART; SM00239; C2; 2.
DR   SMART; SM00142; PI3K_C2; 1.
DR   SMART; SM00144; PI3K_rbd; 1.
DR   SMART; SM00145; PI3Ka; 1.
DR   SMART; SM00146; PI3Kc; 1.
DR   SMART; SM00312; PX; 1.
DR   SUPFAM; SSF48371; ARM repeat; 1.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 2.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   SUPFAM; SSF64268; PX domain; 1.
DR   SUPFAM; SSF54236; Ubiquitin-like; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS51547; C2_PI3K; 1.
DR   PROSITE; PS00915; PI3_4_KINASE_1; 1.
DR   PROSITE; PS00916; PI3_4_KINASE_2; 1.
DR   PROSITE; PS50290; PI3_4_KINASE_3; 1.
DR   PROSITE; PS51546; PI3K_RBD; 1.
DR   PROSITE; PS51545; PIK_HELICAL; 1.
DR   PROSITE; PS50195; PX; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding; Cataract;
KW   Cell membrane; Cytoplasm; Cytoplasmic vesicle; Disease variant; Dwarfism;
KW   Endocytosis; Exocytosis; Golgi apparatus; Kinase; Lipid metabolism;
KW   Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Transferase.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   CHAIN           2..1686
FT                   /note="Phosphatidylinositol 4-phosphate 3-kinase C2 domain-
FT                   containing subunit alpha"
FT                   /id="PRO_0000088795"
FT   DOMAIN          421..509
FT                   /note="PI3K-RBD"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00879"
FT   DOMAIN          682..841
FT                   /note="C2 PI3K-type"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041,
FT                   ECO:0000255|PROSITE-ProRule:PRU00880"
FT   DOMAIN          861..1037
FT                   /note="PIK helical"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00878"
FT   DOMAIN          1105..1383
FT                   /note="PI3K/PI4K catalytic"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   DOMAIN          1422..1538
FT                   /note="PX"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00147"
FT   DOMAIN          1555..1678
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   REGION          1..61
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          2..142
FT                   /note="Interaction with clathrin; sufficient to induce
FT                   clathrin assembly"
FT                   /evidence="ECO:0000269|PubMed:16215232"
FT   REGION          348..367
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          618..639
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          1111..1117
FT                   /note="G-loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          1247..1255
FT                   /note="Catalytic loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          1266..1292
FT                   /note="Activation loop"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00269"
FT   REGION          1488..1493
FT                   /note="Interaction with PtdIns(4,5)P2-containing membranes"
FT                   /evidence="ECO:0000250|UniProtKB:Q61194"
FT   MOTIF           1608..1619
FT                   /note="Nuclear localization signal"
FT                   /evidence="ECO:0000269|PubMed:11606566"
FT   COMPBIAS        17..51
FT                   /note="Basic and acidic residues"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   SITE            244
FT                   /note="Not phosphorylated"
FT                   /evidence="ECO:0000269|PubMed:12719431"
FT   SITE            249
FT                   /note="Not phosphorylated"
FT                   /evidence="ECO:0000269|PubMed:12719431"
FT   SITE            251
FT                   /note="Not phosphorylated"
FT                   /evidence="ECO:0000269|PubMed:12719431"
FT   SITE            254
FT                   /note="Not phosphorylated"
FT                   /evidence="ECO:0000269|PubMed:12719431"
FT   SITE            262
FT                   /note="Not phosphorylated"
FT                   /evidence="ECO:0000269|PubMed:12719431"
FT   SITE            266
FT                   /note="Not phosphorylated"
FT                   /evidence="ECO:0000269|PubMed:12719431"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0007744|PubMed:19413330"
FT   MOD_RES         60
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         108
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648,
FT                   ECO:0007744|PubMed:18691976, ECO:0007744|PubMed:20068231,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         259
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000269|PubMed:12719431,
FT                   ECO:0007744|PubMed:18669648, ECO:0007744|PubMed:18691976,
FT                   ECO:0007744|PubMed:19369195, ECO:0007744|PubMed:19690332,
FT                   ECO:0007744|PubMed:20068231, ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163, ECO:0007744|PubMed:24275569"
FT   MOD_RES         327
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:21406692,
FT                   ECO:0007744|PubMed:23186163"
FT   MOD_RES         338
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:18669648"
FT   MOD_RES         630
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1281
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   MOD_RES         1553
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:23186163"
FT   VAR_SEQ         484..1686
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_056158"
FT   VARIANT         195..1686
FT                   /note="Missing (in OCSKD; no protein detected by Wester
FT                   blot in patient cells)"
FT                   /evidence="ECO:0000269|PubMed:31034465"
FT                   /id="VAR_082616"
FT   VARIANT         1415
FT                   /note="T -> A (in dbSNP:rs11604561)"
FT                   /id="VAR_023333"
FT   MUTAGEN         103..107
FT                   /note="LLLDD->AAAAA: Reduces clathrin binding."
FT                   /evidence="ECO:0000269|PubMed:11239472"
FT   MUTAGEN         254
FT                   /note="S->A: No effect on phosphorylation in vitro."
FT                   /evidence="ECO:0000269|PubMed:12719431"
FT   MUTAGEN         259
FT                   /note="S->A,D,E: Abolishes phosphorylation, no change in
FT                   activity."
FT                   /evidence="ECO:0000269|PubMed:12719431"
FT   MUTAGEN         259
FT                   /note="S->A: Protects from proteolysis."
FT                   /evidence="ECO:0000269|PubMed:12719431"
FT   MUTAGEN         262
FT                   /note="S->A: No effect on phosphorylation in vitro."
FT                   /evidence="ECO:0000269|PubMed:12719431"
FT   MUTAGEN         266
FT                   /note="S->A: No effect on phosphorylation in vitro."
FT                   /evidence="ECO:0000269|PubMed:12719431"
FT   MUTAGEN         1250
FT                   /note="D->A: Abolishes lipid kinase activity. Affects
FT                   clathrin distribution when combined with a truncation
FT                   encompassing the region of clathrin interaction."
FT                   /evidence="ECO:0000269|PubMed:16215232"
FT   MUTAGEN         1488
FT                   /note="R->A: Reduces affinity for PtdIns(4,5)P2-containing
FT                   membranes 7-fold."
FT                   /evidence="ECO:0000269|PubMed:17038310"
FT   MUTAGEN         1490
FT                   /note="V->A: Reduces affinity for PtdIns(4,5)P2-containing
FT                   membranes 7-fold."
FT                   /evidence="ECO:0000269|PubMed:17038310"
FT   MUTAGEN         1491
FT                   /note="L->A: Reduces affinity for PtdIns(4,5)P2-containing
FT                   membranes 5-fold."
FT                   /evidence="ECO:0000269|PubMed:17038310"
FT   MUTAGEN         1493
FT                   /note="R->A: Reduces affinity for PtdIns(4,5)P2-containing
FT                   membranes 23-fold."
FT                   /evidence="ECO:0000269|PubMed:17038310"
FT   MUTAGEN         1503
FT                   /note="R->A: Abolishes interaction with
FT                   PtdIns(4,5)P2-containing membranes."
FT                   /evidence="ECO:0000269|PubMed:17038310"
FT   CONFLICT        5
FT                   /note="S -> F (in Ref. 1; CAA73797)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        15
FT                   /note="S -> F (in Ref. 1; CAA73797)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        483
FT                   /note="N -> K (in Ref. 2; BAG65126)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        796
FT                   /note="F -> C (in Ref. 1; CAA73797)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        799
FT                   /note="K -> R (in Ref. 1; CAA73797)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        922
FT                   /note="V -> G (in Ref. 1; CAA73797)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1129
FT                   /note="M -> L (in Ref. 1; CAA73797)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1450
FT                   /note="R -> W (in Ref. 1; CAA73797)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        1464
FT                   /note="D -> V (in Ref. 1; CAA73797)"
FT                   /evidence="ECO:0000305"
FT   HELIX           1418..1421
FT                   /evidence="ECO:0007829|PDB:2IWL"
FT   STRAND          1422..1433
FT                   /evidence="ECO:0007829|PDB:2AR5"
FT   STRAND          1437..1440
FT                   /evidence="ECO:0007829|PDB:2AR5"
FT   STRAND          1443..1450
FT                   /evidence="ECO:0007829|PDB:2AR5"
FT   STRAND          1457..1462
FT                   /evidence="ECO:0007829|PDB:2AR5"
FT   HELIX           1463..1476
FT                   /evidence="ECO:0007829|PDB:2AR5"
FT   HELIX           1479..1481
FT                   /evidence="ECO:0007829|PDB:2AR5"
FT   STRAND          1491..1495
FT                   /evidence="ECO:0007829|PDB:2AR5"
FT   HELIX           1498..1515
FT                   /evidence="ECO:0007829|PDB:2AR5"
FT   HELIX           1519..1522
FT                   /evidence="ECO:0007829|PDB:2AR5"
FT   HELIX           1525..1530
FT                   /evidence="ECO:0007829|PDB:2AR5"
FT   STRAND          1532..1534
FT                   /evidence="ECO:0007829|PDB:2AR5"
FT   TURN            1535..1537
FT                   /evidence="ECO:0007829|PDB:2IWL"
FT   STRAND          1562..1570
FT                   /evidence="ECO:0007829|PDB:6BTY"
FT   STRAND          1573..1582
FT                   /evidence="ECO:0007829|PDB:6BTY"
FT   STRAND          1587..1590
FT                   /evidence="ECO:0007829|PDB:6BTY"
FT   STRAND          1594..1602
FT                   /evidence="ECO:0007829|PDB:6BTY"
FT   STRAND          1622..1631
FT                   /evidence="ECO:0007829|PDB:6BTY"
FT   HELIX           1634..1637
FT                   /evidence="ECO:0007829|PDB:6BTY"
FT   STRAND          1641..1648
FT                   /evidence="ECO:0007829|PDB:6BTY"
FT   STRAND          1651..1653
FT                   /evidence="ECO:0007829|PDB:6BTY"
FT   STRAND          1656..1664
FT                   /evidence="ECO:0007829|PDB:6BTY"
FT   HELIX           1665..1667
FT                   /evidence="ECO:0007829|PDB:6BTY"
FT   STRAND          1674..1679
FT                   /evidence="ECO:0007829|PDB:6BTY"
SQ   SEQUENCE   1686 AA;  190680 MW;  904AA5470F80DAC6 CRC64;
     MAQISSNSGF KECPSSHPEP TRAKDVDKEE ALQMEAEALA KLQKDRQVTD NQRGFELSSS
     TRKKAQVYNK QDYDLMVFPE SDSQKRALDI DVEKLTQAEL EKLLLDDSFE TKKTPVLPVT
     PILSPSFSAQ LYFRPTIQRG QWPPGLPGPS TYALPSIYPS TYSKQAAFQN GFNPRMPTFP
     STEPIYLSLP GQSPYFSYPL TPATPFHPQG SLPIYRPVVS TDMAKLFDKI ASTSEFLKNG
     KARTDLEITD SKVSNLQVSP KSEDISKFDW LDLDPLSKPK VDNVEVLDHE EEKNVSSLLA
     KDPWDAVLLE ERSTANCHLE RKVNGKSLSV ATVTRSQSLN IRTTQLAKAQ GHISQKDPNG
     TSSLPTGSSL LQEVEVQNEE MAAFCRSITK LKTKFPYTNH RTNPGYLLSP VTAQRNICGE
     NASVKVSIDI EGFQLPVTFT CDVSSTVEII IMQALCWVHD DLNQVDVGSY VLKVCGQEEV
     LQNNHCLGSH EHIQNCRKWD TEIRLQLLTF SAMCQNLART AEDDETPVDL NKHLYQIEKP
     CKEAMTRHPV EELLDSYHNQ VELALQIENQ HRAVDQVIKA VRKICSALDG VETLAITESV
     KKLKRAVNLP RSKTADVTSL FGGEDTSRSS TRGSLNPENP VQVSINQLTA AIYDLLRLHA
     NSGRSPTDCA QSSKSVKEAW TTTEQLQFTI FAAHGISSNW VSNYEKYYLI CSLSHNGKDL
     FKPIQSKKVG TYKNFFYLIK WDELIIFPIQ ISQLPLESVL HLTLFGILNQ SSGSSPDSNK
     QRKGPEALGK VSLPLFDFKR FLTCGTKLLY LWTSSHTNSV PGTVTKKGYV MERIVLQVDF
     PSPAFDIIYT TPQVDRSIIQ QHNLETLEND IKGKLLDILH KDSSLGLSKE DKAFLWEKRY
     YCFKHPNCLP KILASAPNWK WVNLAKTYSL LHQWPALYPL IALELLDSKF ADQEVRSLAV
     TWIEAISDDE LTDLLPQFVQ ALKYEIYLNS SLVQFLLSRA LGNIQIAHNL YWLLKDALHD
     VQFSTRYEHV LGALLSVGGK RLREELLKQT KLVQLLGGVA EKVRQASGSA RQVVLQRSME
     RVQSFFQKNK CRLPLKPSLV AKELNIKSCS FFSSNAVPLK VTMVNADPMG EEINVMFKVG
     EDLRQDMLAL QMIKIMDKIW LKEGLDLRMV IFKCLSTGRD RGMVELVPAS DTLRKIQVEY
     GVTGSFKDKP LAEWLRKYNP SEEEYEKASE NFIYSCAGCC VATYVLGICD RHNDNIMLRS
     TGHMFHIDFG KFLGHAQMFG SFKRDRAPFV LTSDMAYVIN GGEKPTIRFQ LFVDLCCQAY
     NLIRKQTNLF LNLLSLMIPS GLPELTSIQD LKYVRDALQP QTTDAEATIF FTRLIESSLG
     SIATKFNFFI HNLAQLRFSG LPSNDEPILS FSPKTYSFRQ DGRIKEVSVF TYHKKYNPDK
     HYIYVVRILR EGQIEPSFVF RTFDEFQELH NKLSIIFPLW KLPGFPNRMV LGRTHIKDVA
     AKRKIELNSY LQSLMNASTD VAECDLVCTF FHPLLRDEKA EGIARSADAG SFSPTPGQIG
     GAVKLSISYR NGTLFIMVMH IKDLVTEDGA DPNPYVKTYL LPDNHKTSKR KTKISRKTRN
     PTFNEMLVYS GYSKETLRQR ELQLSVLSAE SLRENFFLGG VTLPLKDFNL SKETVKWYQL
     TAATYL
//
